Last updated on October 2018

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Brief description of study

This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).

Clinical Study Identifier: NCT02753127

Contact Investigators or Research Sites near you

Start Over

Mina Boyadzhieva

Healthcare Research Network III, LLC
Tinley Park, IL United States
  Connect »